1 / 44

Fever and Neutropenia

Fever and Neutropenia. Pediatric Resident Education Series. Normal Body Defenses. Barriers – skin, mucosa, etc. Phagocytes – PMN, monocytes, eosinophils Lymphocytes Antibodies Cell mediated immunity Reticulo-endothelial system (RES) Complement. Sites Frequency Organisms Treatments

effie
Download Presentation

Fever and Neutropenia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Fever and Neutropenia Pediatric Resident Education Series

  2. Normal Body Defenses • Barriers – skin, mucosa, etc. • Phagocytes – PMN, monocytes, eosinophils • Lymphocytes • Antibodies • Cell mediated immunity • Reticulo-endothelial system (RES) • Complement

  3. Sites Frequency Organisms Treatments Outcomes Co-morbities Exposures School Home Food Water Pets Immunizations Family History Recent chemotherapy i.e., immune suppression? Infection Questions

  4. Primary work-up • Barriers: • History, Physical exam • Phagocytes: • CBC/diff • Lymphocytes: • CBC/diff, Quantitative Ig • RES: • blood smear (Howell-Jolly bodies?) • Complement: • rare

  5. Secondary work-up • Barriers: • Biopsy with EM • Phagocytes: • tests for mobilization, chemothaxis, opsonization, ingestion, killing (NBT test) • Lymphocytes: • subsets (T, B, NK, others), antibody titers, skin tests, isohemaggluinins, function tests (mixing T, B cells) • RES: • Tc Scan • Complement: • Factor titers

  6. Neutropenia

  7. Pneumonia in a neutropenic patient • Empiric antibiotics • Bacteria: cefepime, tobramycin, vancomycin • Mycoplasma: azithromycin • Pneumocystis: Bactrim • Viral: acyclovir • Fungal: Ambisome, other

  8. Pneumonia in a neutropenic patient.. • Lavage: if done well, gives 75% of pathogens found on biopsy • Frequently worsens lung scans • Biopsy: • usually worsens lung status • Empiric antibiotic therapy: • if wrong drugs, then lavage/biopsy needed in sicker patients • In one small trial, outcome of empiric therapy was equivalent to that of biopsy (Pizzo et al).

  9. Fever, neutropenia pearls • Limited ability to mount cellular response means signs/symptoms of infection may be subtle • Treat the rectum with respect (limit exams, no medications) • Pneumonia without tachypnea is rare • UTI without dysuria must be considered in a female

  10. Fever in Neutropenia: Definitions • Fever • Single oral temp of > 38.3 • Neutropenia • Severe: ANC < 200 (rising septicemia risk) • Moderate: 200-500 (rising serious infection risk) • Mild: 500-1000 • Duration: 7-day cut-off

  11. Evaluation • Careful physical, (including perineal/perianal palpation) • CBC; UA; cultures from all lines/ports and infected-appearing exit sites • Imaging as indicated by exam • Repeat exam daily; culture daily for fever spikes > 38.3oC or chills (the ideal time to culture is just before the fever rises!)

  12. Site specific cultures • Diarrhea • (C diff, rotavirus, Stool culture, O and P) • Skin- if wound present-culture • CVL site • (bacterial, fungal, mycobacteria) • Viral cultures • Mucosal or cutaneous vesicular/ulcerated lesions • Respiratory viral PCR

  13. Management – 1 • Broad spectrum single antibiotic (cefepime) • Add tobramycin if strong suspicion of gram negative organism • Add vancomycin if sick or skin involvement • Still febrile after 72 hours? • Add or change antibiotics • Still febrile after 5-7 days? • Consider anti-fungal therapy

  14. Management - 2 • No pathogen • Continue antibiotics until afebrile x 24 hours AND evidence of marrow recovery • If afebrile, but NO evidence of marrow recovery, continue antibiotics for 10-14 days • Pathogen • Treat until afebrile with negative cultures AND ANC > 500 for 7-10 days.

  15. Management: fever without neutropenia • Exam; blood cultures • other w/u as suggested by H&P • If NO line and no obvious pathogen: • No antibiotic unless left shift, or unexpected upswing in ANC • If line: • Consider observation vs. ceftriaxone with reassessment in 24 hours (or less)

  16. ISDA/ASCO guidelines • Fever is defined as a single oral temperature of > 38.3C (101F) or a temperature of > 38.0C (100.4F) for 1hour. • Neutropenia is defined as an ANC < 500 or < 1000 with a predicted decrease to < 500. • Oral therapy allowed (Amox/Clav) for low-risk patients: no bacterial focus, no systemic sxs (hypotension, rigors) other than fever, good access. Preferably also recovering monocytes. • See table and chart

  17. General comments • The incidence of bacteremia in febrile neutropenic pediatric patients is estimated at 4 to 36% • Many studies document bacteremia in patients who lack concerning exam findings • At least one study suggests many parents do NOT want outpatient Rx, even for low-risk children[JCO 22(19):3922-6, 2004 Oct. 1] • In adult studies from Japan and South America, outpatient management (typically with oral antibiotics) is referenced as a “standard;” meta-analysis supports the safety of that approach [J Antimicrob Chemo 54(1):29-37, 2004 Jul] • Most bacteremia in F&N patients is gm(+)[Clin Infx Dz 39Suppl S25-31, 2004 Jul 15]

  18. Indiana U. – F/N Rx factors JCO 14(3);919-24, 1996 March • 115 consecutive episodes of F&N in 72 pediatric oncology patients. • Analysis showed the only predictive factors to be the absolute monocyte count, AMoC and admission temperature, but NOT remission status, mucositis, ill appearance, GI symptoms, cellulitis, use of GCSF, or ANC at admission. • Patients then grouped % positive cultures • low (AMoC > 100, any temp) 0 • intermediate (AMoC < 100, T < 39) 19 • high risk (AMoC < 100, T > 39) 48

  19. UC Davis – F/N Rx factors Pediatric Emergency Care. 20(2):79-84, 2004 Feb 303 events in 143 patients, of which 36 (11.9%) received a critical care therapy Higher temperature at presentation and capillary filling time (CFT) of >3 seconds retained significance in the multivariable analysis Positive and negative predictive values of the presence of either T ≥ 39.5oC or CFT of >3 seconds were 35% and 91%, respectively.

  20. Sloan-Kettering – F/N Rx factors Cancer 77(4):791-8, 1996 Feb. 15 161 patients pediatric oncology patients with 509 episodes of fever studied retrospectively for risk of bacteremia Clinical features correlating with increased risk of + cultures: chills, hypotension, requirement for fluid resuscitation, diagnosis of leukemia or lymphoma NOT whether or not leukemia pt’s were in remission. ICU admit and/or death predicted ONLY by ANC < 100 after 48 hours and persistent fever (both; not an and/or)

  21. Children’s Hosp of Eastern Ontario: early diagnosis, PO antibiotics? J Pediatr Hematol Oncol. 2000 Sep-Oct;22(5):405-11 Randomized, double-blind, placebo-controlled study design:73 patients at low-risk with episodes of F&N were Discharged while still neutropenic: 37 with oral cloxacillin and cefixime vs. 36 with placebos. Low-risk criteria included: afebrile for more than 24 hours, negative blood culture results at 48 hours, absence of clinical sepsis, cancer in bone marrow remission, and absence of comorbid conditions. 5 patients re-admitted with fever; no difference between groups; 1 patient (placebo) re-admitted with + cultures; no fatalities. See also: JCO 22(18):3784-9, 2004 Sept 15

  22. UT SW and Children’s Med Ctrs. Early diagnosis, PO antibiotics? Clin Infx Dz 25:74-8,1997 July 580 episodes of F&N in 253 peds onc patients; 333 d/c’d prior to reaching an ANC of 500. [N.B. here “fever” = > 38.5 x 1 or > 38.0 x 2 in 24h] 25% were d/c’d on oral Abx, for specific (focal) infections Lower risk: (-)blood cultures x > 24h, afeb x 24 hrs, appeared well, some evidence of marrow recovery. The groups (discharge early or not) differed: those going early were less likely to be on GCSF and had fewer mean days of fever; also had a more likely final diagnosis of FUO. 6% re-admit rate for recurrent fever (NOT different from re-admit rate in those discharged at ANC > 500), 15 of which had no evidence of marrow recovery retrospectively. No cases of bacteremia in discharged cohort. Similar studies (same centers) Cancer 74(1):189-96, 1994 July 1, JCO 8(12):1998-2004, 1990 Dec., J Peds 128(6):847-9, 1996 June

  23. NCI and participants (run out of U of Nebraska): PO vs. IV antibiotics Randomized, double-blind, placebo-controlledstudy of patients (age 5 to 74 years) w/ F&Nduring chemotherapy. Neutropenia < 10 days, no other underlying conditions. Assignedto PO ciprofloxacin plus amoxicillin–clavulanateor IV ceftazidime. All hospitalized. 116 episodes in each group(84 patients in the PO group and 79 patients in theIV group). Treatment was successful without the need for modificationsin 71 percent of episodes in the PO group and 67 percentof episodes in the IV group (difference betweengroups, 3%; 95% CI: –8% to 15%; p=0.48). There were no deaths. NEJM 341(5):305-311

  24. MASCC risk-index score [for adults] Multinational Association (for) Supportive Care in Cancer • Predictive factors for risk of serious complications of F&N, weighted • Absence of sxs/mild sxs (x5) • Absence of hypotension (x4) • Absence of COPD (x4) • Presence of solid tumor or, if liquid tumor, absence of prior fungal infx (x4) • Outpatient at the time (x3) • Absence of dehydration (x3) • Age < 60 yrs (x2) • < 21 = “low risk” Validation study @ CHOP: Uys et al, Supportive care in Cancer 12(8):555-60, 2004 Aug.

  25. 38.0 38.3 38.4 38.5 39 39.1 38.0556 38.3333 38.6111 100.4 100.94 101.12 101.3 102.2 102.38 100.5 101 101.5 Temp conversions

  26. Fever < 39 Well-appearing No chills No hypotension No dehydration If bone marrow disease, in remission If solid tumor, not progressive dz No serious bacterial focus No co-morbidities or end-organ dysfunction No severe mucositis APC, monocytes, platelets No peri-rectal sxs Consider other GI sxs No diffuse cellulitis Expected count recovery in < 7 days > 12 mos old Reliable social situation Not on high-risk Rx No BMT pt’s No AML pt’s No induction pt’s No Burkitt pt’s Consider if intensification phase Low-risk status (for ANC 200-500)

  27. Purpura in DIC

  28. Purpura in DIC

  29. HSV Infections

  30. Invasive Aspergillosis • CT scan of chest • may diagnose aspergillosis • A halo sign • characteristic of angioinvasive organisms • Galactomannan assay • detects aspergillus fungal wall (PCR test) • 81% sensitivity, 89% specificity • Serial monitoring • Order as ‘miscellaneous microbiology test’

  31. SEPTIC SHOCK • Fever or hypothermia • Tachycardia • Vasodilation • Change in mental status • Inconsolable, Irritability • Lack of interaction with parents • Inability to be aroused

  32. Clinical diagnosis • Fever, hypothermia • Decreased perfusion • Prolonged capillary refill > 2 seconds-cold shock • Flash capillary refill- warm shock • Diminished (cold) or bounding (warm) pulses • Mottled extremities • Decreased urine output (< 1cc/kg/hour) • Hypotension

  33. Monitoring and Testing • Pulse oximeter • Continuous cardiac monitor • Blood pressure • Temperature • Urine output • Glucose and ionized calcium

  34. Fluid Resuscitation • Rapid fluid boluses of 20 mL/kg (isotonic saline or colloid) by push while watching for new onset of rales, gallop rhythm, hepatomegaly, and/or increased work of breathing. • In the absence of these clinical findings, fluid can be administered to as much as 200 mL/kg in the first hour. The average requirement is 40-60 mL/kg in the first hour. Fluid should be pushed with the goal of attaining normal perfusion and blood pressure. • Transfuse PRBCs, Platelets, FFP if needed

  35. From ABP Certifying Exam Content Outline • Recognize the need for immediate evaluation of a febrile child who is neutropenic as a result of chemotherapy • Recognize recurrent bacterial infections as a manifestation of quantitative or qualitative leukocyte disorders • Know that a total leukocyte count and a leukocyte differential count are needed to diagnose neutropenia • Know that neutropenia is usually defined as a neutrophil count <1000/mm3 • Know that children with severe neutropenia may become infected with their own skin and bowel flora • Recognize mucosal ulcerations as a sign of neutropenia

  36. From ABP Certifying Exam Content Outline, continued • infections in the compromised host • Know the major opportunistic infections seen in the immunocompromised host, eg, cancer and neutropenia, AIDS, nephrotic syndrome, asplenia, sickle cell disease • Know that an accepted antibiotic regimen for an immunocompromised child with fever should be effective against Pseudomonas aeruginosa and staphylococci • Recognize that aspergillosis is a fungal infection usually of the lungs, and occurs almost exclusively in patients with impaired host responses

  37. From ABP Certifying Exam Content Outline, continued • Identify varicella as a life-threatening illness in a patient receiving chemotherapy, and know that varicella-zoster immune globulin should be given immediately after exposure to varicella • Know the indications for the use of varicella-zoster immune globulin after exposure to varicella in immunocompromised patients and in certain high-risk infants • Know that varicella-zoster immune globulin should be given within 96 hours after exposure to varicella

  38. From ABP Certifying Exam Content Outline, continued • Understand that live-virus vaccines should not be given during chemotherapy • Understand which immune-deficient patients should not receive a live-virus vaccine • Plan an immunization schedule for an immunedeficient patient

  39. Credits • …as listed • Meghen Browning MD

More Related